BioSpace News Archive

Cullinan Oncology, Inc. a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, announced its participation in the following upcoming investor conferences.

Vittoria Biotherapeutics has announced today that accomplished life sciences leader, Rosemary Mazanet, M.D., Ph.D., has joined the Company as Chief Medical Officer.

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced the expansion of its ongoing Phase I/II trial evaluating the safety and efficacy of its lead candidate, RECCE® 327 (R327), in patients with diabetic foot infections (DFI) based on the interim data analysis and the study achieving its primary endpoints.

Pyxis Oncology, Inc. today announced that it has agreed to sell 8,849,371 shares of its common stock at a price of $4.78 per share.

Minerva Neurosciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to the Company’s New Drug Application (NDA) for roluperidone for the treatment of negative symptoms in patients with schizophrenia.

ReWalk Robotics Ltd., a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, announced its financial results for the three months and full year ended December 31, 2023.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2023 financial results after market close on Tuesday, March 5 , 2024.

ReNAgade Therapeutics today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.

Ensysce Biosciences, Inc. today announced that it has received notice from The Nasdaq Stock Market LLC as described in a decision dated February 26, 2024, that the Company may continue its listing on The Nasdaq Capital Market tier with an extension to May 13, 2024.

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Amit Etkin, M.D., Ph.D., founder and chief executive officer, will present a company overview at the TD Cowen 44th Annual Healthcare Conference on Tuesday, March 5, 2024, at 1:30 pm ET.